Drug Trial News

RSS

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

The U.S. affiliate of Ipsen today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

17 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Significant percentage of completed drug clinical trials are not disclosed to public

A significant percentage of completed drug clinical trials, especially those funded by industry, are not disclosed to the public, years after being completed-a trend that "threatens the validity of the clinical research literature in the U.S.," according to a study led by a Boston University School of Public Health (BUSPH) researcher.

16 Jul 2014

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

16 Jul 2014

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.

15 Jul 2014

CYD-TDV vaccine shows moderate protection against dengue in Asian children

The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.

14 Jul 2014

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection.

10 Jul 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

10 Jul 2014

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD).

9 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics Biotech Inc. today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045).

8 Jul 2014

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Consumers worldwide spend billions of dollars each year on probiotic foods and supplements. But studies evaluating probiotics - microorganisms believed to aid digestive health - have been limited.

4 Jul 2014

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.

3 Jul 2014

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

AIMM Therapeutics, a leading human therapeutic antibody company, today announced that its partner MedImmune, LLC, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.

2 Jul 2014

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.

1 Jul 2014

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.

From Baxter International Inc. 1 Jul 2014

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.

1 Jul 2014

UCSF researchers complete first Internet-based clinical trial for children with autism

UC San Francisco researchers have completed the first Internet-based clinical trial for children with autism, establishing it as a viable and cost effective method of conducting high-quality and rapid clinical trials in this population.

1 Jul 2014

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.

1 Jul 2014

Drug Trial News

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Significant percentage of completed drug clinical trials are not disclosed to public

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

CYD-TDV vaccine shows moderate protection against dengue in Asian children

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Integrated therapies can reduce depression by half among people with low vision due to AMD

Pain control in osteoarthritis patients

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

UCSF researchers complete first Internet-based clinical trial for children with autism

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News